The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Open accessAbstract
The central nervous system (CNS) possesses powerful local and global immunosuppressive capabilities that modulate unwanted inflammatory reactions in nervous tissue. These same immune-modulatory mechanisms are also co-opted by malignant brain tumors and pose a formidable challenge to brain tumor immunotherapy. Routes by which malignant gliomas coordinate immunosuppression include the mechanical and functional barriers of the CNS; immunosuppressive cytokines and catabolites; immune checkpoint molecules; tumor-infiltrating immune cells; and suppressor immune cells. The challenges to overcoming tumor-induced immunosuppression, however, are not unique to the brain, and several analogous immunosuppressive mechanisms also exist for primary tumors outside of the CNS. Ultimately, the immune responses in the CNS are linked and complementary to immune processes in the periphery, and advances in tumor immunotherapy in peripheral sites may therefore illuminate novel approaches to brain tumor immunotherapy, and vice versa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“The provenances of these processes have clear implications for brain tumor immunotherapies, such as dendritic cell-based vaccines (147, 148), that aim to exploit tumor antigen presentation to augment tumor immunity.”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 3×
“tumor proliferation (97, 98) Immunosuppression (various) (99); tumor invasion (100); tumor”
BackgroundPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Cited by
Brain immunology and immunotherapy in brain tumours
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 722
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Saha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Immune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., & Yu, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1085-3 · Cited by 286
Ock, C.-Y., Keam, B., Kim, S., Lee, J.-S., Kim, M., Kim, T. M., Jeon, Y. K., Kim, D.-W., Chung, D. H., & Heo, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2834 · Cited by 269
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Multiple Faces of the Glioblastoma Microenvironment
Șovrea, A. S., Boșca, B., Melincovici, C. S., Constantin, A.-M., Crintea, A., Mărginean, M., Dronca, E., Jianu, M. E., Suflețel, R., Gonciar, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020595 · Cited by 26
Metadata
- Authors
- Perng, P., & Lim, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2015-07-06
- Volume
- 5
- Pages
- 153-153
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1509288539
- Cited by
- 166
- References
- 53
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.